MétaCan
Menu
Back to cohort
Record W4411434879 · doi:10.1192/bjp.2025.125

Moderators of antidepressant augmentation versus switch in the OPTIMUM randomised controlled trial

2025· article· en· W4411434879 on OpenAlexafffund
Helena K. Kim, Jordan F. Karp, Helen Lavretsky, Daniel M. Blumberger, Patrick J. Brown, Alastair J. Flint, Emily Lenard, J. Philip Miller, Charles F. Reynolds, Steven P. Roose, Eric J. Lenze, Benoit H. Mulsant

Bibliographic record

VenueThe British Journal of Psychiatry · 2025
Typearticle
Languageen
FieldMedicine
TopicTreatment of Major Depression
Canadian institutionsUniversity Health NetworkCentre for Addiction and Mental HealthUniversity of Toronto
FundersCanadian Institutes of Health ResearchNational Institutes of HealthUniversity of California, San FranciscoUniversity of TorontoVanderbilt UniversityUniversity of PennsylvaniaUniversity of Texas Southwestern Medical CenterWake Forest UniversityPatient-Centered Outcomes Research Institute
KeywordsBupropionMedicineAntidepressantDepression (economics)Randomized controlled trialNortriptylineMontgomery–Åsberg Depression Rating ScaleRating scaleAripiprazoleInternal medicineAnxietyPsychologyPsychiatryDepressive symptomsSchizophrenia (object-oriented programming)AmitriptylineSmoking cessation

Abstract

fetched live from OpenAlex

Background Older adults with treatment-resistant depression (TRD) benefit more from treatment augmentation than switching. It is useful to identify moderators that influence these treatment strategies for personalised medicine. Aims Our objective was to test whether age, executive dysfunction, comorbid medical burden, comorbid anxiety or the number of previous adequate antidepressant trials could moderate the superiority of augmentation over switching. A significant moderator would influence the differential effect of augmentation versus switching on treatment outcomes. Method We performed a preplanned moderation analysis of data from the Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM) randomised controlled trial ( N = 742). Participants were 60 years old or older with TRD. Participants were either (a) randomised to antidepressant augmentation with aripiprazole (2.5–15 mg), bupropion (150–450 mg) or lithium (target serum drug level 0.6 mmol/L) or (b) switched to bupropion (150–450 mg) or nortriptyline (target serum drug level 80–120 ng/mL). Treatment duration was 10 weeks. The two main outcomes of this analysis were (a) symptom improvement, defined as change in Montgomery–Asberg Depression Rating Scale (MADRS) scores from baseline to week 10 and (b) remission, defined as MADRS score of 10 or less at week 10. Results Of the 742 participants, 480 were randomised to augmentation and 262 to switching. The number of adequate previous antidepressant trials was a significant moderator of depression symptom improvement ( b = −1.6, t = −2.1, P = 0.033, 95% CI [−3.0, −0.1], where b is the coefficient of the relationship (i.e. effect size), and t is the t -statistic for that coefficient associated with the P -value). The effect was similar across all augmentation strategies. No other putative moderators were significant. Conclusions Augmenting was superior to switching antidepressants only in older patients with fewer than three previous antidepressant trials. This suggests that other intervention strategies should be considered following three or more trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.020
metaresearch head score (Gemma)0.034
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.020
Threshold uncertainty score0.107

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0200.034
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0060.007
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0070.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.302
Teacher spread0.289 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueThe British Journal of PsychiatrySame topicTreatment of Major DepressionFrench-language works237,207